Abbvie Inc

ABBV

$114.70

+26.1% (1 year change)

Avg closing price

Price range

Warren Buffett Holding value: $2.44 Billion Daniel Loeb Holding value: $338 Million Jim Simons Holding value: $228 Million Stanley Druckenmiller Holding value: $140 Million Ken Griffin Holding value: $69.1 Million Cathie Wood Holding value: $63.4 Million George Soros Holding value: $17.2 Million Joel Greenblatt Holding value: $11.9 Million Jeremy Grantham Holding value: $3.58 Million Mario Gabelli Holding value: $2.32 Million Tom Russo Holding value: $1.45 Million Ray Dalio Holding value: $0 Donald Yacktman Holding value: $0

Market Cap

$203 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

52 Week Range

$77.26 - $118.28

The lowest and highst price in the last 52 weeks.

Price-Earnings Ratio

39.88x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

Dividends per Share

$4.87 (4.24%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Revenue & Earnings

Balance Sheet

Share Statistics

Market Cap $203 Billion
Enterprise Value $279 Billion
Dividend Yield $4.87 (4.24%)
1 Year Return +30.3%
52-Week High $118.28
52-Week Low $77.26
Beta 0.62
Outstanding Shares 1.77 Billion
Avg 30 Day Volume 6.57 Million

Valuation

P/E Ratio 39.88
PEG 224.15
Earnings per Share $2.92
Price to Sales Ratio 4.1
Price to Book Ratio 16.39
Revenue to Enterprise Value 5.55
EBIT to Enterprise Value 21.22
Total Debt to Enterprise Value 0.31
Debt to Equity 6.24

Profitability

Revenue $50.2 Billion
Gross Profit $32.5 Billion
EBIT $13.1 Billion
Net Income $5.09 Billion
Profit Margin 10.14%
Quarterly Earnings Growth (YoY) +17.8%
Return on Equity 37.12%
Return on Assets 3.38%
Return on Invested Capital 11.08%

News

AbbVie puts an end to Botox trade secrets suit, imposes royalty, license deal on competitor Evolus

AbbVie puts an end to Botox trade secrets suit, imposes royalty, license deal on competitor Evolus

The crown jewel of AbbVie's big-dollar acquisition of Allergan, Botox is one of the most recognizable brands in pharma — and both drugmakers have worked overtime to protect its advantage. After sco...

Endpoints News Endpoints News, 4 months ago
Global Uveitis treatment Market (2020 to 2026) - Featuring AbbVie, Allergan and Bausch Health Companies Among Others - ResearchAndMarkets.com

Global Uveitis treatment Market (2020 to 2026) - Featuring AbbVie, Allergan and Bausch Health Companies Among Others - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Global Uveitis treatment Market 2020-2026" report has been added to ResearchAndMarkets.com's offering. The global uveitis treatment market is projected to witness cons...

Business Wire Business Wire, 4 months ago
AbbVie shares continue to trade in a bull market after better than expected Q4 results | Invezz

AbbVie shares continue to trade in a bull market after better than expected Q4 results | Invezz

AbbVie (NYSE: ABBV) shares weakened last week by more than 3%, and the current price stands around $104. According to analysts, it’s not hard to find reasons to invest in AbbVie, and as long the pr...

Invezz Invezz, 4 months ago
To improve your user experience we use cookies.